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“The important thing is to not stop questioning. Curiosity has its own reason for existing.”  
- Albert Einstein

  
ABSTRACT 
The platelet derived growth factors (PDGFs) and their tyrosine kinase receptors play an essential role 
during development, in adult tissue homeostasis and in several pathological events. PDGF-CC, a ligand for 
PDGFRα, is secreted as an inactive dimer. Proteolytic activation of PDGF-CC is mediated by the serine 
protease tissue plasminogen activator (tPA) and subsequently this allows binding of the active PDGF-CC 
dimer to and signaling through PDGFRα. In the blood tPA is involved in fibrinolysis and recombinant tPA is 
the only FDA approved treatment of acute ischemic stroke. However, thrombolytic therapy with tPA is 
highly limited due to an increased risk of intracerebral hemorrhage and it has been hypothesized that this 
is caused by unique activities of tPA in the neurovascular unit (NVU). 
To better understand the biological function of tPA and PDGF-CC signaling in the central nervous system 
(CNS) we first characterized the effect of tPA ablation on brain development in mice (Paper I). We found 
that tPA deficient mice presented with rearrangements in the cerebrovascular tree, including a shift 
towards small diameter vessels as compared to wild-type mice. Additionally, we found ventricular 
malformations, including asymmetry of the lateral ventricles and a distorted ependymal lining. Since 
PDGF-C deficient mice have previously been described with asymmetric lateral ventricles, this potentially 
provides a first in vivo link between tPA and PDGF signaling in CNS development. 
In Paper II we aimed to identify the mechanism underlying abnormal ventricular development in PDGF-C 
deficient mice. Our findings suggest that PDGF-CC/PDGFRα signaling controls radial glia migration and 
differentiation, subsequently affecting ependymal development and maturation. This in turn might 
explain the ventricular expansion and asymmetry associated with PDGF-C ablation.  
tPA mediated activation of PDGF-CC and subsequent PDGFRα signaling has been associated with 
increased cerebrovascular permeability in CNS disorders. However, activation of PDGF-CC by tPA in vitro 
has been described as inefficient, thus we investigated potential co-factors needed for tPA mediated 
activation of PDGF-CC in the NVU in Paper III. We found that Mac-1 on microglia is required to facilitate 
efficient activation of PDGF-CC by tPA. Subsequently this enhanced PDGFRα phosphorylation in the NVU, 
resulting in loss of BBB integrity and intracerebral hemorrhage. In support of Mac-1 being a co-factor for 
PDGF-CC/PDGFRα activation, we found that Mac-1 deficient mice showed decreased BBB permeability 
and smaller infarct size in an experimental model of ischemic stroke.  
Previous studies have shown that the tyrosine kinase inhibitor imatinib improves neurological and 
functional outcome after ischemic stroke via inhibition of PDGFRα signaling in both mice and patients. In 
Paper IV we described the mechanism how imatinib ameliorates stroke pathology. In the acute phase we 
found that imatinib preserved BBB integrity and reduced reactive gliosis, whereas in the chronic phase 
blocking PDGFRα signaling in the NVU in ischemic stroke moderated scar formation.  
Collectively these findings will help us to better understand the role of tPA in the NVU and provide new 
insights regarding the role of PDGF-CC/PDGFRα signaling in CNS development and in ischemic stroke. 
Ultimately this might lead to novel treatment strategies to improve outcome following ischemic stroke.  
WISSENSCHAFTLICHE ZUSAMMENFASSUNG 
Die PDGFs (Platelet Derived Growth Factor) gehören zu einer Familie von Wachstumsfaktoren, bestehend 
aus PDGF-AA, PDGF-BB, PDGF-CC und PDGF-DD und den dazugehörigen Tyrosinkinase-Rezeptoren 
PDGFRα und PDGFRβ. PDGF-CC wird als inaktives Dimer sezerniert und muss vor der Signaltransduktion 
durch PDGFRα, von dem gewebespezifischen Plasminogen Aktivator (tPA) aktiviert werden. tPA ist 
bekannt durch seine Rolle in der Fibrinolyse. In dieser klassischen Funktion wird tPA zur Auflösung von 
Blutgerinnseln eingesetzt. Tatsächlich ist tPA die einzige FDA anerkannte medikamentöse Behandlung von 
akutem ischämischem Schlaganfall. Die Anwendung ist jedoch aufgrund des Risikos von Hirnblutungen 
sehr limitiert. Dieses Risiko wird auf besondere, teils unbekannte Funktionen von tPA im Gehirn und auf 
die Blut-Hirn-Schranke zurückgeführt. 
Um diese besondere Funktion von tPA im Gehirn besser zu verstehen, charakterisierten wir in Paper I tPA 
defiziente Mäuse. In diesen Mäusen führt das Fehlen von tPA zu einer Neuorganisation des zerebralen 
Blutgefäßsystems, einschließlich einer Verlagerung zu kleineren Gefäßdurchmessern. Zusätzlich fanden 
wir eine Fehlbildung des zerebralen Ventrikelsystems in Form von vergrößerten, asymmetrischen 
lateralen Ventrikeln. Ähnliche Fehlbildungen wurden zuvor auch in PDGF-C defizienten Mäusen 
beschrieben. Dementsprechend zeigen diese Erkenntnisse eine erste Verbindung von tPA und PDGF-C in 
der Entwicklung der zerebralen Ventrikel auf. Die molekularen Hintergründe, durch die das Fehlen von 
PDGF-C zu ventrikulären Fehlbildungen führt, sind nicht bekannt und wurden in Paper II erforscht. Wir 
zeigen, dass vermutlich fehlerhafte Zellmigration und Zelldifferenzierung zu mangelhafter Entwicklung 
und Reife von ependymalen Zellen entlang der Ventrikelwand führen und folglich zu ventrikulären 
Fehlbildungen. 
Aktivierung von PDGF-CC durch tPA und anschließende Signaltransduktion durch PDGFRα wird mit 
erhöhter Permeabilität der Blut-Hirn-Schranke in diversen Erkrankungen des zentralen Nervensystems 
(ZNS) verbunden. Die Aktivierung von PDGF-CC durch tPA in vitro, außerhalb eines lebenden Organismus, 
wird jedoch als mangelhaft beschrieben. In Paper III untersuchten wir, welche möglichen Co-Faktoren um 
die Blut-Hirn-Schranke in einem lebenden Organismus die Aktivierung von PDGF-CC unterstützen 
könnten. Wir fanden heraus, dass LRP1 und Mac-1 auf Mikroglia zur leistungsfähigen Aktivierung von 
PDGF-CC durch tPA notwendig sind. Zusätzlich zeigten wir, dass das Fehlen von Mac-1, Mäuse vor 
erhöhter Permeabilität der Blut-Hirn-Schranke schützt und auch zu kleineren Schlaganfällen führt. 
Dementsprechend stellt die Voraussetzung dieser Co-Faktoren eine Limitation für die Aktivierung von 
PDGF-CC durch tPA dar und bietet eine neuartige Möglichkeit, um die momentan vorhandene 
Behandlung von ischämischem Schlaganfall zu verbessern. Zusätzlich konnten wir kürzlich in einer 
klinischen Studie zeigen, dass der Tyrosinkinasen Inhibitor Imatinib durch Hemmung der PDGFRα 
Signaltransduktion den Krankheitsverlauf eines ischämischen Schlaganfalls abschwächt und zu 
verbessertem neurologischen Ausgang führt. Der darunter liegende Mechanismus ist jedoch weitgehend 
unbekannt. In Paper IV beschreiben wir, dass die Hemmung von PDGFRα durch Imatinib die Integrität der 
Blut-Hirn-Schranke schützt und Narbenbildung so wie auch reaktive Gliose in Mäusen mit 
experimentellem ischämischem Schlaganfall mildert. 
Diese Erkenntnisse helfen die Rolle von tPA um die Blut-Hirn-Schranke besser zu verstehen und bieten 
neue Einblicke in die Funktion von PDGF-CC/PDGFRα Signaltransduktion in der Entwicklung des ZNS und 
bei ischämischem Schlaganfall. Die Schlüsselrolle der Blut-Hirn-Schranke bietet eine Möglichkeit zu 
verbesserten Behandlungsstrategien und dadurch verbesserten Krankheitsausgang für Schlaganfall 
Patienten.   
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1 INTRODUCTION  
1.1 The Platelet-Derived Growth Factor (PDGF) Family 
The Platelet-Derived Growth Factor (PDGF) family consists of five known disulphide-bonded dimers 
formed from four different polypeptide chains, PDGF-A, PDGF-B, PDGF-C, and PDGF-D, and their 
tyrosine kinase receptors, PDGFRα and PDGFRβ [1].  
The PDGF ligands belong to the superfamily of Vascular Endothelial Growth Factors (VEGFs). These 
factors all contain a growth factor domain (GFD) with a pattern of eight highly conserved cysteine 
residues necessary for dimerization, receptor binding and activation [2]. PDGF-A and PDGF-B 
polypeptides contain N-terminal pro-domains, which need to be intracellularly removed by either 
furin or related proprotein convertases in order for these factors to become active [3]. Further, 
PDGF-A and PDGF-B polypeptides exhibit a C-terminal basic retention motif that binds and interacts 
with extracellular matrix components via electrostatic interactions between the retention motif and 
negatively charged groups in heparin sulfate [1, 2]. It was long believed that PDGF-AA and PDGF-BB 
dimers were the only ligands for PDGFRα and PDGFRβ, respectively, but the fact that PDGF-A 
deficient mice displayed a less severe phenotype [4, 5] than PDGFRα deficient mice [6] implied the 
existence of an additional ligand for PDGFRα. Search for such a ligand led to the discovery of PDGF-
CC [7], and later also to the rather unexpected discovery of a novel ligand for PDGFRβ, PDGF-DD [8]. 
PDGF-CC and PDGF-DD are secreted as full-length inactive dimers with N-terminal CUB-domains 
linked to the respective GFD via a hinge region of 80-90 amino acids [7, 9]. The CUB-domains need to 
be proteolytically removed in order to allow receptor binding of the active dimer and subsequent 
signaling. The GFD, the hinge region as well as the CUB-domain are required for specific interactions 
with the proteolytic enzymes and cleavage occurs extracellularly after secretion of the inactive 
dimers. Full length PDGF-CC is proteolytically processed by tissue plasminogen activator (tPA) [9, 10] 
(Fig.1), whereas PDGF-DD is cleaved by the other known plasminogen activator, urokinase 
plasminogen activator (uPA) [11, 12] or matriptase [13].  
 
Fig.1: Extracellular processing of PDGF-CC. 
PDGF-CC is produced and secreted as an inactive dimer requiring extracellular proteolysis for activation. Full 
length PDGF-CC is proteolytically cleaved by tPA, resulting in an active growth factor domain (GFD) dimer able 
to bind and stimulate PDGFRα signaling. 
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The PDGF receptors are tyrosine kinase receptors of ~170 and 180 kDa [2]. Each PDGF receptor 
contains an intracellular tyrosine kinase domain, a trans-membrane domain and five extracellular 
immunoglobulin-like domains (illustrated in Fig.2). The extracellular domains are involved in ligand 
binding and receptor dimerization, which subsequently leads to conformational changes and auto-
phosphorylation of tyrosine residues in the intracellular domains. This intracellular phosphorylation 
enables interaction with different families of SH2-domain containing molecules, including members 
of the PI3-kinase family, Phospholipase C-γ (PLC-γ) and the Src family, as well as Grb2, SHP-2, GAP 
and Stat molecules [2]. Following activation of the receptor, clathrins are recruited, thereby leading 
to internalization of the receptor from the cell surface by endocytosis for either degradation or 
recycling [14].  
In vivo experiments have shown that, after intracellular processing and secretion, the PDGF-AA 
dimer signals via PDGFRα and PDGF-BB mainly via PDGFRβ [2], whereas, after extracellular 
proteolysis, PDGF-CC signals via PDGFRα [7]. PDGF-DD signals via PDGFRβ [8], however in vivo this 
has so far only been shown in pathology such as fibrotic processes, various cancers and 
cardiovascular disease [1, 15-17] and, unlike the other PDGFRβ ligand, PDGF-BB, PDGF-DD seems to 
be dispensable for murine embryonic development [18]. The differential effect of PDGF-DD and 
PDGF-BB signaling through PDGFRβ might be explained by the recent findings that Neuropilin 1 
(NRP1) is a co-receptor for PDGF-DD/PDGFRβ signaling but not for PDGF-BB/PDGFRβ signaling [19]. 
In vitro PDGF-AB and PDGF-BB (in addition to PDGF-AA and PDGF-CC) have been demonstrated to 
bind PDGFRα. Furthermore, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD have been shown to bind to 
a heterodimerized PDGFRαβ receptor complex [20] (see Fig.2 for schematic illustration of the ligand 
binding profile to the PDGFRs). The physiologic relevance of these in vitro findings has however yet 
to be determined.  
 
 
Fig.2: Receptor interactions of the PDGFs 
PDGF-AA, PDGF-BB and PDGF-CC homodimers as well as the PDGF-AB heterodimer signals via PDGFRα whereas 
PDGF-BB and PDGF-DD signals via PDGFRβ. PDGF-CC, PDGF-BB and PDGF-DD homodimers as well as the PDGF-
AB heterodimer have been shown to interact with PDGFRαβ. 
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PDGFRα, but not PDGFRβ, signaling has been linked to primary cilia [21, 22]. Primary cilia are 
signaling hubs on eukaryotic cells that coordinate signaling pathways in cell-cycle control, migration, 
differentiation during development and tissue homeostasis [23, 24]. Along these lines, activation of 
PDGFRα on primary cilia has been found, via activation of Akt and the Mek1/2-Erk1/2 pathways, to 
control cell migration and differentiation processes [21, 24, 25]. Defects in assembly or function of 
primary cilia lead to numerous developmental disorders and diseases potentially due to aberrant 
signal transduction [24]. 
 
1.1.1 Roles of PDGF-CC and PDGFRα Signaling in Embryonic 
Development 
PDGFs act primarily as paracrine growth factors and their expression is spatio-temporally regulated 
during development and disease. The expression patterns of the PDGF ligands and their receptors 
during embryonic development have been shown to be distinct but partially overlapping [1]. 
Deletion of the genes encoding PDGFRα and its ligands PDGF-AA and PDGF-CC in mice have provided 
valuable information about their biological function during embryonic development. Knockout of 
PDGF-A [4, 5, 26] or PDGFRα in mice [6] is lethal, although deletion of PDGFRα results in a phenotype 
similar, but more severe than the phenotype caused by ablation of the PDGF-A gene [6]. PDGFRα 
signaling was found to be critical for embryonic development in mice, as all PDGFRα deficient 
embryos die at mid-gestation. It was established that PDGFRα signaling is required for the migration 
of various cell populations during developmental processes, including migration of cranial neural 
crest cells and spreading of oligodendrocyte precursors in the spinal cord [6]. The documented 
phenotypes associated with PDGFRα ablation included, in addition to the defects found in PDGF-A 
deficient mice [5], skeletal defects such as spina bifida (incomplete closure of the neural tube), cleft 
palate and abnormalities of the rib cage, but also, hemorrhaging and subepidermal blistering [6]. The 
discrepancy between the phenotypes of PDGF-A and PDGFRα deficiency could not be explained by 
PDGF-BB signaling through PDGFRα, as double PDGF-A/B null embryos did not display the additional 
PDGFRα defects [7]. This therefore led to the search for, and later the identification, of PDGF-CC as a 
novel PDGFRα ligand [7]. Ablation of PDGF-C in 129S1/Sv mice has since been shown to cause 
perinatal lethality due to feeding and respiratory difficulties associated with a complete cleft of the 
secondary palate, with 95% of the pups dying at postnatal day (P) 1 and none surviving until weaning 
[27]. The PDGF-C deficient mice displayed subepidermal blisters and spina bifida occulta, thus 
resembling some of the phenotypes reported for the PDGFRα knockouts that had not been 
associated with PDGF-A ablation. Combined deletion of PDGF-A and PDGF-C was found to 
recapitulate the PDGFRα knockout phenotype, indicating that PDGF-AA and PDGF-CC are the major 
PDGFRα ligands in murine embryonic development [27]. It has later been established that targeted 
deletion of PDGF-C in mice results in different phenotypes depending on the genetic background of 
the mice. In a C57BL/6 background, deletion of PDGF-C was reported to be compatible with 
postnatal life, although loss of PDGF-CC signaling was found to result in various central nervous 
system (CNS) abnormalities [28] (discussed in section 1.1.3).  
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1.1.2 Physiological Roles of PDGF-CC and PDGFRα Signaling in the 
Adult 
Due to the importance of PDGF-CC and PDGFRα signaling during embryonic development and 
pathology, much less focus has been on understanding the role of this signaling system in adult 
physiology. In most adult tissues the expression of the PDGFRα is usually low, as it is mainly needed 
to maintain tissue homeostasis. However, during various tissue remodeling processes, such as 
wound healing and angiogenesis, as well as inflammation and disease, PDGFRα expression increases 
[1]. Due to the generally low activity of PDGFRα signaling in the adult, pharmacological usage of 
imatinib, a tyrosine kinase antagonist of ABL, c-kit and the PDGFRs, was considered as safe. 
Consequently, imatinib is today successfully used to treat patients suffering from 
myelodysplastic/myeloproliferative diseases associated with PDGFRα gene rearrangements as well 
as for treatment of BCR-ABL driven chronic myeloid leukemia (CML) and c-kit positive 
gastrointestinal stromal tumors (GIST) [29, 30]. Nevertheless, several short-term side effects occur 
with imatinib treatment, including edema, muscle cramps, nausea, diarrhea, fatigue, and headache, 
as well as long-term effects such as cerebral edema, multiple sclerosis, hepatic- and  pulmonary 
toxicities, dermatitis and pancreatitis [31]. Whether this is due to imatinib’s effect on PDGFRα 
signaling or its activity against c-kit or ABL is not established.  
In conditional knockout mice, where PDGFRα was completely inactivated in adult mice but intact 
during development, it was shown that PDGFRα plays a crucial role in connective tissue remodeling 
and wound healing [32]. This, by controlling deposition of collagen and fibronectin in extracellular 
matrix production. Further these mice revealed decreased angiogenesis and improper fibroblast 
recruitment [32]. Taken together this suggests various different roles of PDGFRα signaling in adult 
physiology. Corresponding conditional knockout studies to investigate the role of PDGF-CC in the 
adult have yet to be performed and as a result less is known about this factor’s role in physiologic 
processes.  
 
1.1.3 Expression and Function of PDGF-CC and PDGFRα in the CNS 
1.1.3.1 Expression 
High expression of PDGF-C transcripts have been found in many organs including the brain [33]. 
During CNS development PDGF-C is found in neuronal progenitors of the developing brain, in the 
choroid plexus and vascular elements of the pia mater, as well as in the neural tube and in the 
ventral horn of the spinal cord [33]. Ding et al. also reported PDGF-C expression in the cerebellum 
and neurogenic derivates of neural crest cells [34]. In the adult murine brain PDGF-C is highly 
expressed on both transcriptional and protein level in the cortex, the hippocampus, the amygdala 
and the septum separating the lateral ventricles [28]. In single cell analyses of the neurovascular unit 
(NVU), PDGF-C transcript was found to be highly expressed in arteriolar and arterial smooth muscle 
cells, as well as in astrocytes and vascular fibroblast like cells [35, 36]. In addition, PDGF-C expression 
was found in non NVU cells, with the highest expression recorded in oligodendrocyte precursor cells 
(OPCs) and less in mature oligodendrocytes [35, 36].  
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In the CNS, high expression of PDGFRα is found in OPCs and glia cells but also in cells undergoing 
neuronal development and neurons of the olfactory bulb, the cerebral cortex, the hippocampus as 
well as in neuroepithelial cells during early development [37, 38]. PDGFRα expression is also found in 
perivascular cells in the NVU [28, 39-41]. The identity of the PDGFRα expressing cells in the NVU is 
however a matter of some debate [28, 35, 39, 42, 43]. Immunofluorescent studies suggest that 
PDGFRα in the NVU is expressed on perivascular astrocytes along arterioles and pre-capillary 
arterioles throughout the CNS [28, 39, 44], and single cell sequencing suggests these cells to be 
vascular fibroblast-like cells [35]. Nevertheless, ablation of PDGFRα expression from the perivascular 
pool can be achieved in mice utilizing site-specific recombination with glial-fibrillary acidic protein 
(GFAP)-driven Cre expression [40]. 
 
1.1.3.2 Function 
During CNS development PDGF-CC has been reported to play a role in cerebral vascular 
development. This since PDGF-C deficiency in C57BL/6 mice was found to cause an overall increase 
in vascular density and diameter as well as incorrect investment of vascular smooth muscles cells 
around vessels [28]. In addition, cerebral ventricular malformations, such as asymmetry of the 
cerebral lateral ventricles, displaced septum and an abnormal ependymal lining were noticed [28]. 
The mechanism how aberrant PDGF-CC signaling leads to abnormal ventricular development 
remains elusive and is further investigated in Paper II. 
Deletion of PDGF-C in mice is associated with a milder form of skeletal defect (spina bifida occulta) 
[27] than the skeletal defect associated with ablation of PDGFRα (spina bifida) [6]. However, deletion 
of one PDGFRα allele in the PDGF-C deficient mice resulted in manifestation of the spina bifida 
phenotype [45]. This incomplete closure of the neural tube is not normally seen in PDGFRα 
heterozygous mice, indicating a gene dosage effect of PDGFRα signaling in neural tube closure. In 
addition, these double mutant Pdgfc-/-;PdgfrαGFP/+ mice also displayed abnormal meninges with 
neuronal over-migration in the cerebral cortex [45].   
In the adult CNS, proliferation, differentiation and migration of OPCs has been shown to be 
stimulated by PDGFRα [46], and later it was found in in vitro experiments that microglia produce 
factors stimulating oligodendrocyte development via PDGFRα signaling [47]. Interestingly, PDGF-CC 
was mentioned as a crucial factor for OPC recruitment and activation in mice injected with glioma 
cells [48], although the effect of PDGFRα signaling on OPC differentiation and migration is normally 
ascribed to the effect of PDGF-AA signaling [5].  
In addition, PDGFRα signaling is well known to regulate blood-brain barrier (BBB) integrity [39, 49] 
and in this context PDGFRα signaling is controlled by tPA mediated proteolytic activation of PDGF-CC 
[39] (discussed in further detail in section 1.3).  
Collectively, this illustrates that PDGF-CC and PDGFRα are important for normal CNS development 
and that this signaling pathway is involved in physiological CNS processes in adult mice, including 
OPC proliferation, differentiation and migration [46-48], as well as BBB regulation [39].   
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1.2 The Multiple Roles of tPA  
tPA is a multidomain trypsin-like serine protease best known for its role in fibrinolysis in blood 
plasma, where it converts plasminogen into the broad specificity protease plasmin [50-52]. Plasmin 
in turn controls fibrin degradation and the conversion of latent matrix metalloproteinases (MMP) 
into active MMPs leading to degradation of extracellular matrix [50-52]. tPA consists of 530 amino 
acids and is composed of a finger domain, a growth factor domain, two kringle domains and the 
protease domain [52]. The protease domain is the active site of tPA and consists of the amino acids 
serine, aspartic acid and histidine and is located in the C-terminal region [52]. Activation of the 
plasminogen system by infusion of plasminogen activators like tPA is one approach for thrombolytic 
therapy to achieve lysis of blood clots. Recombinant tPA is currently the only FDA approved 
treatment of acute ischemic stroke, but evidence suggests a role of tPA in hemorrhagic 
transformation of an ischemic stroke due to unique activities in the NVU [39, 53]. The NVU is a 
functional unit of endothelial cells, forming the blood vessel lining, neurons and non-neuronal cells, 
including vascular mural cells, astrocytes and microglia, on the abluminal side (Fig.3). The close 
proximity of these different cell types is critical for paracrine regulations and normal CNS function 
including neurovascular coupling and vascular integrity [54].  
 
1.2.1 Expression and Function of tPA in the CNS 
tPA is mainly produced and secreted from endothelial cells, but this pool of tPA is nearly exclusively 
released into the bloodstream [52]. In the CNS, tPA is also synthesized in neurons, where it is stored 
in vesicles and released in response to neuronal activity to regulate various biological responses, 
including cerebrovascular responses [55]. In the adult murine brain, tPA is highly expressed in the 
cortex, the amygdala, the mossy fiber pathway of the hippocampus, as well as the cerebellum and 
the hypothalamus [56]. High expression of tPA is also reported in the human CNS, where tPA is found 
in neurons of many different brain structures, including in the hippocampus and amygdala of the 
limbic system. High expressions were found in the human hippocampus, especially in pyramidal 
neurons of the cornu ammonis and granule neurons of the dentate gyrus. Additional to neuronal 
expression, tPA is found in microglia and astroglia and has been associated with gliosis in disease 
[57]. tPA activity and expression in the CNS is regulated by its inhibitor neuroserpin and by binding of 
the cytoplasmic polyadenylation element binding (CPEB) protein leading to extension of tPA mRNA 
polyadenylation and an increase in tPA protein synthesis [55, 58, 59]. 
 
1.2.2 Roles of tPA in CNS Development 
During development tPA is involved in neuronal development and survival [60], migration [61, 62], 
and cerebrovascular as well as cerebroventricular development (Paper I [41]).  
In in vitro studies it has been shown that granule neurons possess binding sites for tPA [63] and that 
tPA is released at the neuronal growth cone [64], suggesting a role of tPA in neurite growth and 
migration. In neural progenitor cells this was later shown to be via Wnt/β-catenin signaling [65]. 
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Further, PC12 cells, a pheochromocytoma cell line from the adrenal gland, showed faster migration 
and regeneration of neurites when transfected to overexpress tPA [62] and tPA deficient mice 
displayed delayed migration of cerebellar granule neurons [61], suggesting a direct role of tPA in 
neuronal migration. It should be noted that tPA overexpression in mutant mice has been described 
to result in dendritic underdevelopment, thus challenging the above in vitro results [60]. 
 
1.2.3 Physiological Roles of tPA in the Adult 
In the adult CNS, tPA has been reported to be involved in many different processes, including 
neurovascular coupling [40, 66], excitotoxicity [67-69], neurometabolic effects [70, 71], regulation of 
neuronal activity via the N-methyl-D-aspartate (NMDA) receptor [69, 72], microglial activation [73-
75] and regulation of vascular permeability [39, 76]. High expression of tPA in the mossy fibers of the 
hippocampus suggests a role of tPA in memory and learning [58]. Further, tPA expression is 
increased during activity-dependent forms of synaptic plasticity [77] and in Purkinje neurons of rats 
during motor learning [78]. Accordingly, tPA deficient mice show learning deficits in both rate and 
extent [79, 80] and stimulation with tPA enhances late phase long-term potentiation (L-LTP), 
synaptic formation and strength, the underlying mechanisms of learning and memory [81]. 
It has been suggested that the pleiotropic effects reported for tPA in physiologic and pathologic 
processes in the CNS, may be a consequence of its role in the NVU regulating cerebrovascular 
responses and subsequently parenchymal homeostasis [55, 59]. The effect of tPA in the NVU has 
been shown to be mediated by a plasminogen-independent activation of PDGF-CC on the abluminal 
side of the vessel wall. This, since injection of tPA into the blood of unchallenged mice does not 
increase BBB permeability, whereas injection into the cerebrospinal fluid does [39]. Further, this 
activity of tPA in the NVU was shown to be independent of uPA, plasminogen and MMP-9, thus 
suggesting another substrate in tPA-mediated regulation of cerebrovascular permeability [76]. In 
vitro it was shown that tPA is capable of cleaving latent PDGF-CC in a plasminogen-independent 
manner, generating an active PDGF-CC ligand that can bind and activate PDGFRα [9] (Fig.1 and 2). 
This tPA mediated activation of PDGF-CC was later confirmed in vivo, when it was shown that tPA-
induced cerebrovascular changes are facilitated by activation of PDGF-CC and subsequent PDGFRα 
signaling on perivascular astrocytes [39]. 
Further, it has been shown that tPA is released into the perivascular space in response to neuronal 
activity, where it is thought to control the process of neurovascular coupling, possibly through a 
PDGF-CC/PDGFRα dependent mechanism [55, 66]. Neurovascular coupling describes an increase in 
local cerebral blood flow in response to increased neuronal activity, which is critical for energy 
supply to activated neurons and clearance of metabolic waste products [82]. Underlining a role of 
tPA in neurovascular coupling is the fact that penetrating arterioles have been shown to control this 
process and tPA has been shown to be expressed in close proximity to arterioles in the CNS [40, 66]. 
Additionally, tPA has been reported to reduce vessel reactivity to increased luminal pressure and 
vasoactive mediators, and tPA can directly reduce cerebral vascular resistance and systemic blood 
pressure [55]. Under pathologic conditions the role of tPA mediated activation of PDGF-CC/PDGFRα 
in the NVU has been extensively studied and is discussed in further detail below. 
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1.3 tPA and PDGF-CC/PDGFRα Signaling in CNS Pathology 
During CNS development both tPA and PDGF-CC have been associated with cerebroventricular 
formation in mice [28, 41], providing a first link between tPA and PDGF-CC signaling in vivo. In 
addition, aberrant PDGFRα signaling has been associated with hydrocephalus formation [83], the 
most well characterized form of cerebroventricular malformation in patients (also referred to as 
ventriculomegaly). These findings are intriguing because the molecular mechanisms underlying 
brain ventricle formation remain poorly understood. 
In adult mice, tPA mediated activation of PDGF-CC/PDGFRα has been shown to be involved in several 
neurological disorders, including ischemic stroke [39] (discussed in further detail in section 1.3.2), 
spinal cord injury [84], traumatic brain injury [85], multiple sclerosis [86], ALS [87], and seizures [40]. 
For all these disorders inhibition of PDGF signaling has been shown to reduce BBB permeability and 
restore vascular barrier properties, leading to improved outcome of the disease.  
 
1.3.1 Hydrocephalus / Ventriculomegaly 
Hydrocephalus is a CNS disorder characterized by expansion of the cerebral ventricles and 
accumulation of cerebrospinal fluid (CSF). Accumulation of CSF leads to increased intracranial 
pressure and subsequent compression of the surrounding tissue [88]. It is a common neurological 
disorder associated with cognitive and physical impairment, creating a yearly economic burden in 
the United States of $2 billion for pediatric hydrocephalus alone [89].  
The etiology of hydrocephalus is widely discussed and related to multiple causes. So far 
hydrocephalus has been linked to hemorrhage and infections [90, 91], overproduction [92-94] or 
disturbed absorption of CSF [94-96] as well as disturbances in CSF flow due to an obstruction [96-99] 
or defect motile cilia structure and function on ependymal cells [100].  
CSF is produced by highly specialized epithelial cells in the choroid plexus in the lateral ventricles. 
From the lateral ventricles CSF circulates through the interventricular foramina to the third ventricle 
and via the cerebral aqueduct to the fourth ventricle before reaching the subarachnoid spaces, 
where it is reabsorbed at the arachnoid granulations into the internal jugular vein by a pressure-
dependent gradient [101, 102]. CSF circulation is thought to be achieved by propulsion of motile cilia 
on ependymal cells lining the ventricular system, pulmonary respiration and cardiac pulsations [102]. 
Thus, venous insufficiency [103], arteriovenous malformations [104, 105] and cardiac failure [106] 
have been described to contribute to hydrocephalus development. Further, altered CSF absorption 
in patients and in mice deficient in the water channel aquaporin-4, has been linked to hydrocephalus 
[94, 95, 107]. Another reason for disturbed CSF flow resulting in hydrocephalus formation is an 
obstruction of the narrow passage through the cerebral aqueduct. This is for example seen in Wrp 
deficient mice, where abnormal cell migration and astrogliosis has been shown to lead to blockage of 
the cerebral aqueduct and subsequently to hydrocephalus [98]. Obstruction in the aqueduct due to 
increased secretory activity of the subcommissural organ has also been associated with 
hydrocephalus [97].  
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CSF is mainly composed of water, transporting proteins, ions, neurotransmitters and glucose [102] 
and a change in the osmotic gradient of CSF due to excess molecules can result in hydrocephalus 
formation [108]. Decreasing CSF protein levels has been successful to reverse or prevent post 
hemorrhagic hydrocephalus in several cases [109, 110]. Interestingly, patients with hydrocephalus 
present elevated levels of VEGF in the CSF [111] and VEGF infusion and increased VEGF signaling 
leads to ependymal changes and hydrocephalus in rats [111, 112]. 
In addition to the above discussed causes of hydrocephalus, signaling on non-motile primary cilia has 
gained increasing interest. This, since patients with the ciliopathy Laurence-Moon-Biedl syndrome or 
Bardet-Biedl syndrome present with occasional hydrocephalus [113, 114]. Primary cilia serve as a 
signaling sensor extending from nearly all cell types [115] and several studies have linked impaired 
signaling on primary cilia to hydrocephalus development [83, 116-119]. PDGFRα signaling has been 
shown to depend on primary cilia [21] and it has been demonstrated that aberrant PDGFRα signaling 
in primary cilia on neuronal progenitor cells leads to hydrocephalus formation [83]. This, due to a 
decrease of PDGFRα/NG2 positive progenitor cells in the subventricular zone (SVZ) [83]. Disruption 
of the SVZ, including loss of neural progenitor cells, has repeatedly been associated with 
hydrocephalus [120]. As discussed above, PDGFs and their tyrosine kinase receptors play an 
important role during development [1] and ablation of PDGF-CC has been shown to result in 
ventricular malformations such as asymmetry of the lateral ventricles and hypoplastic development 
of the septum separating the lateral ventricles [28]. In addition, our findings presented in Paper I 
show that mice deficient in tPA, the protease responsible for PDGF-CC cleavage and activation, 
display enlarged asymmetric lateral ventricles as well [41]. Collectively, this suggests a role of tPA 
mediated activation of PDGF-CC/PDGFRα signaling in normal ventricle development and that 
defective signaling might be involved in hydrocephalus formation, although the precise mechanism 
has yet to be determined. 
 
1.3.1.1 The Role of Ependymal Cells in Hydrocephalus Development 
Ependymal cells act as a barrier between the CSF and the brain parenchyma, are involved in CSF 
homeostasis and provide structural and metabolic support to cells in the SVZ. Mature ependymal 
cells carry an apical cluster of motile cilia contributing to CSF propulsion [121-123]. Many groups 
have linked hydrocephalus development to altered ependymal motile cilia function and mutations in 
genes that disrupt cilia structure and function lead to impaired CSF flow and consequently to 
expansion of the ventricles [118, 119, 124-128].  
Besides impaired ependymal motile cilia, ependymal cell maturation and integrity have been 
associated with hydrocephalus development. This, since loss of junctional proteins such as Jam3 and 
Mpdz in mice has been described with hydrocephalus [129, 130]. Interestingly, both Jam3 and Mpdz 
deficient mouse models show signs of astrogliosis as a repair mechanism to ependymal defects and 
ependymal denudation, which in Mpdz deficient mice resulted in a narrowed cerebral aqueduct 
[130]. 
Ependymal cells arise from a subpopulation of radial glia cells [131] and Six3 has been shown to be 
required for ependymal cell differentiation and maturation. Thus, Six3 deficiency results in aberrant 
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ependymal cell maturation and consequently in abnormal neuroblast migration and differentiation 
and hydrocephalus development [132]. Further, mice deficient for the transcription factor NFIX, 
which has been described to promote neural stem cell differentiation, displayed ependymal deficits 
including partial loss of the ependymal layer lining the cerebral ventricles [133]. This is especially 
intriguing, since ependymal denudation has also been reported in humans with hydrocephalus [134-
136]. Additionally, overexpression of Nestin (a marker for radial glia) has been associated with 
immature glial cells and ependymal cell loss has been reported in postmortem hydrocephalic brains 
[137]. 
Taken together, this underlines the importance of ependymal cell maturation and integrity in the 
context of hydrocephalus development. 
 
1.3.2 Ischemic Stroke  
Stroke is a leading cause of morbidity and mortality. 40% of stroke patients remain with moderate 
functional impairments and 15-30% with severe disability, resulting in a tremendous economic 
burden [138].   
The majority of strokes are ischemic, with hemorrhagic bleeding stroke accounting for approximately 
10-13% of all strokes [138]. An ischemic stroke is caused by a thrombus blocking the cerebral blood 
flow to an area of the brain causing oxygen deprivation resulting in cell death. Hemorrhagic strokes 
generally have a worse prognosis than ischemic strokes [139], and a hemorrhagic conversion of an 
ischemic stroke increases stroke severity and worsens outcome [140]. Recombinant tPA is currently 
the only FDA approved thrombolytic treatment of acute ischemic stroke, but its use is greatly limited 
due to the requirement of administration within 4.5 hours after the onset of symptoms. This, 
because of concerns of increased BBB permeability and transformation to a hemorrhagic stroke, 
which is currently affecting about 7% of treated patients [140, 141]. Hemorrhagic transformation of 
an ischemic stroke is defined by bleeding with petechial hemorrhage in the infarction area and 
parenchymal hematoma accompanied by neurological deterioration [142]. The risk to develop 
hemorrhagic complications has been linked to the amount of time passed before treatment, 
symptom severity, age, blood glucose levels, thrombocytopenia, hypertension, congestive heart 
failure and leukoaraiosis [140, 142]. Additionally, besides the risk of hemorrhagic complications, tPA 
has been reported to promote neuronal degeneration after cerebral ischemia [143]. Taken this into 
account, less than 5% of stroke patients are eligible for tPA therapy [141]. However, intravenously 
administered tPA for the treatment of ischemic stroke is associated with improved functional 
outcome [144] and if administered within 90 minutes from stroke onset tPA treatment allows nearly 
complete recovery [141]. The American Heart Association/ American Stroke Association predicate 
that the beneficial effect outweighs the risk and strongly recommend tPA treatment of eligible 
patients despite the risk of hemorrhagic complications, but also emphasize the urgent need for 
further research on the treatment of ischemic stroke [145].  
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1.3.2.1 Blood-brain Barrier Dysfunction in Ischemic Stroke 
The mechanism how thrombolytic tPA might lead to hemorrhagic complications is not fully 
understood, but it appears to be due to the unique activities of tPA in the CNS, including cleavage 
and activation of PDGF-CC [55].  
tPA deficient mice display significantly smaller strokes compared to wild-type controls but after 
intravenous administration of tPA, stroke volume and neuronal damage increase to a comparable 
volume as in wild-type controls [143]. This, as well as tPA activity found in the ischemic area of tPA 
deficient mice after intravenous administration of tPA, suggests that exogenous tPA administered for 
thrombolysis can cross the BBB and exacerbate stroke volume and neuronal damage [143]. 
Additional to a smaller stroke volume, tPA deficient mice exhibit decreased Evan’s blue extravasation 
after ischemic stroke as compared to wild-type controls indicating that these mice are protected 
from stroke induced BBB leakage [76]. Also, plasminogen deficient mice are not protected against 
BBB permeability induced by intraventricular injection of tPA and an NMDAR antagonist cannot 
preserve BBB integrity either [76]. Thus, these studies reveal that tPA is both necessary and sufficient 
to induce opening of the BBB in a plasminogen- and NMDAR-independent manner [76]. About the 
same time as these studies were published, PDGF-CC was identified as a new substrate for tPA [9]. 
However, these in vitro studies revealed that activation of PDGF-CC by tPA was rather inefficient and 
LRP1 (low-density lipoprotein receptor-related protein-1) was shown to enhance tPA mediated 
PDGF-CC activation [39]. Later it was also demonstrated that the integrin Mac-1 on microglia acts 
together with LRP1 to facilitate tPA mediated activation of PDGF-CC in the NVU [146]. Further, 
activation of PDGF-CC by tPA has been shown to impair BBB integrity following ischemic stroke in 
mice, via activation of PDGFRα on perivascular astrocytes (Fig.3), and treatment with the PDGFRα 
antagonist imatinib has been shown to reduce this increase in BBB permeability [39]. This has later 
been confirmed by different groups [147-149] and a phase II clinical study recently revealed that 
imatinib is both safe and tolerable and reduces neurological disability in patients receiving 
intravenous tPA treatment after stroke [150].  
In pathological conditions like ischemic stroke, increased BBB permeability has been shown to be 
mediated by tPA in response to the increased energy and metabolic demand in neurons following 
ischemia [55]. Excessive BBB disruption subsequently leads to extravasation of substances like 
fibrin(ogen) from the blood stream and infiltration of leukocytes from the vascular space into the 
brain parenchyma, triggering an inflammatory response and an increase in MMP9 activity [151, 152]. 
Interestingly, increased MMP9 activity has been described in the context with tPA induced 
hemorrhage and inhibition of MMP9 directly, or inhibition of the MMP9 pathway, results in 
decreased BBB disruption after ischemic stroke in rabbits, mice and rats [153-157]. BBB disruption is 
thought to occur in phases, with MMP9 being involved in a second phase in both animal models 
[158] and patients [159] and infiltrating neutrophils have been described as a source of MMP9 
involved in the later phase of BBB opening [160]. 
Based on these findings, changes in the cerebrovascular permeability have been hypothesized to 
underlie the neurotoxic effects associated with thrombolytic tPA in the CNS after ischemic stroke. 
Following intravenous treatment with thrombolytic tPA after ischemic stroke, this exogenous tPA 
presumably enters into the brain parenchyma through a compromised BBB and exacerbates BBB 
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breakdown via intensified PDGF-CC cleavage and PDGFRα signaling, thereby leading to severe tissue 
injury. In line with these findings, higher levels of PDGF-CC in the plasma of stroke patients have 
been associated with an increased risk of hemorrhagic transformation [55]. Controversially, a 
neuroprotective role of tPA during stroke has been proposed. This role of tPA was ascribed to tPA-
induced increase in GLUT3 expression and glucose uptake, thereby meeting the increased metabolic 
demand of neurons during ischemia [70], although this needs to be further investigated in in vivo 
models.  
 
Fig3: The neurovascular unit and blood-brain barrier disruption following ischemic insult.  
The neurovascular unit consists of endothelial cells, vascular mural cells, astrocytes and microglia in a 
functional interaction with neuronal cells. Upon an ischemic insult, increased activity of tPA leads to removal 
of the PDGF-CC CUB-domains and subsequent PDGFRα signaling. This results in vascular mural cell and 
astrocyte detachment and consequential BBB breakdown and release of blood born substances into the brain 
parenchyma. 
 
1.3.2.2 Immune Response in Ischemic Stroke 
Inflammation plays an important role in the pathology of ischemic stroke, as the brain responds to 
the ischemic insult with an acute and a subacute / chronic immune reaction, critical to tissue damage 
and healing. Thus, immune deficient animals have been described with reduced stroke size after 
transient middle cerebral artery occlusion (tMCAO) [161-164] and accordingly neuroimaging of 
stroke patients associated increased numbers of peripheral leukocytes and neutrophils with larger 
infarct volumes [165]. 
The inflammatory response to ischemic stroke is characterized by pro-inflammatory molecules 
released from the injured tissue triggering an immune response and by a rapid activation of resident 
microglia. This initial phase is followed by a subacute phase defined by infiltration of circulating 
immune cells such as neutrophils, T-cells, B-cells and monocytes / macrophages in both animal 
models of ischemic stroke [146, 166-168] and in humans [169-171]. Interestingly, a study recently 
described an effect of thrombolytic tPA on the systemic immune response after tMCAO in mice but 
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whether this affects the number of infiltrating immune cells into the ischemic brain parenchyma 
remains to be seen [172]. 
Resident microglia have a controversial dual role in the acute response after ischemic stroke, as 
microglia polarization produces either the pro-inflammatory M1 or the neuroprotective M2 
phenotype [173]. Microglial polarization towards the pro-inflammatory M1 phenotype has been 
described to be mediated by ischemic neurons releasing Fas ligand [174]. Thereafter M1 microglia 
contributes to neuronal damage and apoptosis as M1 microglia produces pro-inflammatory 
mediators such as TNF-α (tumor necrosis factor-α), ROS, interleukin-1β, CD14, CCL2 and iNOS [175, 
176]. Further it has been shown that microglia promote increased BBB permeability after ischemic 
stroke by enhancing tPA mediated activation of PDGF-CC [146] and by tPA-mediated upregulation of 
MMP9 [177]. On the contrary, M2 microglia has been associated with neuroprotective effects after 
ischemic stroke, since M2 activated microglia release anti-inflammatory cytokines such as IL-4, IL-10 
and transforming growth factor-β [178, 179]. This is supported by the fact that IL-4 deficiency in mice 
leads to worsened outcome accompanied by increased inflammation after tMCAO [180].  
As early as 30 minutes after an ischemic insult, neutrophils infiltrate the ischemic brain, peaking 3 
days after cerebral ischemia in mice and rats [168, 181]. Neutrophils produce ROS and release pro-
inflammatory molecules such as IL-1β, IL-6, IL-8, CCL2 and TNF-α [182]. Thus, pharmacologic 
depletion of neutrophils has been associated with decreased infarct volumes [183-187] and 
decreased edema after reperfusion injury [183]. Infiltrating neutrophils are a direct source of MMP9 
in the ischemic brain [160], thus potentially contributing to increased BBB permeability in both 
animal models [158] and stroke patients [159].  
T-cells contribute in the subacute phase 72 to 96 hours post occlusion [188] and T-cell deficient 
animals display reduced stroke size after tMCAO [161-164]. However, the role of T-cells in ischemic 
stroke progression is rather perplexing. This, since CD4+ and CD8+ T-cells have been associated with 
a pro-inflammatory response [163, 189], whereas regulatory T-cells have been described as 
neuroprotective, as they countervail the pro-inflammatory cytokines TNF-α and IFN-γ via IL-10 [190]. 
In fact, depletion of regulatory T-cells in mice elevates pro-inflammatory cytokine expression in the 
ischemic brain and results in increased infarct size [190]. Additionally, CD4+ TH2 cells have been 
reported to secrete anti-inflammatory cytokines (IL-4, IL-5, IL-10, IL-13) whereas CD4+ TH1 cells may 
contribute to stroke pathogenesis by secreting pro-inflammatory cytokines such as IL-2, IL-12, IFN-γ 
and TNF- α [189]. Also, docking of regulatory T-cells at the injured vessel wall, mediated by CCR5, is 
protective against early BBB disruption following ischemic stroke, attributed to inhibition of 
neutrophil release of MMP9 [191].  
B-cells were found to be protective after ischemic stroke, as intravenous injection of IL-10 secreting 
B-cells reduced both infarct size and infiltration of inflammatory T-cells [192]. Cognitive impairment 
and dementia has however been proposed to be mediated by B-cell infiltration after stroke [193]. 
Overall, the inflammatory response after ischemic stroke is defined by complex cellular interactions 
and shows both beneficial and adverse effects on stroke pathology. 
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1.3.2.3 The Glial Scar 
Upon CNS injury, reactive astrocytes, NG2 glia / OPCs, meningeal and vascular derived fibroblasts 
and microglia form the glial scar around the area of tissue damage.  
CNS injury is accompanied by cell death, BBB damage and inflammation. Microglia are among the 
first cells responding to CNS injury by proliferation and migration to the site of injury, where they are 
involved in phagocytosis of cellular debris, regulation of neuronal excitability and trophic neuronal 
support [194]. Extracellular matrix, consisting of collagens, laminins, and glycoproteins such as 
chondroitin sulfate proteoglycans (CSPGs), both support and inhibit CNS regeneration and begins to 
form shortly after injury [195].  
A second proliferative phase is characterized by cell proliferation and migration. Astrocytes become 
highly proliferative and undergo morphological changes resulting in cellular hypertrophy [196]. 
Hypertrophic reactive astrocytes form a reticular structure and synthesize and deposit CSPGs in the 
extracellular matrix [196]. Reactive astrocytes are crucial in scar formation since mice lacking GFAP 
and vimentin display less organized glial scarring [197]. NG2 glia is, like astrocytes, characterized by 
hypertrophy, increased proliferation and expression of proteoglycans following CNS insult [198] and 
participates in scar formation by stabilizing dystrophic axons within the hostile lesion environment 
and differentiate into oligodendrocytes, thereby contributing to remyelination [194, 196]. NG2 
positive OPCs migrate towards the lesion, orchestrating formation of a structurally layered scar 
[196]. Fibroblast-related cells such as perivascular fibroblasts, meningeal fibroblasts and pericytes 
further contribute to scar formation [199]. Additionally, neural stem cells give rise to neural 
progenitors migrating to the injury sites [195].  
In a third phase of tissue remodeling a compact scar has formed, building a structural and functional 
barrier sealing the lesion and protecting the surrounding parenchyma [195]. 
Often the glial scar, and the created inhibitory environment, has been viewed as limiting to CNS 
regeneration. As mentioned above, reactive astrocytes synthesize and deposit high amounts of 
CSPGs, including growth-inhibitory factors, thereby inhibiting neurite regeneration and functional 
recovery after CNS injury [194, 196]. CSPGs have also been reported to prevent oligodendrocyte 
maturation and thus remyelination in a mouse model of demyelination and spontaneous 
remyelination [200]. Further, endothelin-1, which is secreted by reactive astrocytes, acts as a 
negative regulator of NG2 glial differentiation and functional remyelination [201]. Moreover, NG2 
positive cells have been described to form synapse-like contacts, trapping axons and creating an 
additional barrier to regeneration [202]. 
While the glial scar shows negative effects on regenerative processes, it is crucial to restrict the area 
of damage as well as the inflammatory response and maintain extracellular ion and fluid balance, 
thus protecting the surrounding healthy CNS tissue [203]. Reactive astrocytes were shown to have a 
role in BBB repair, leukocyte infiltration, demyelination as well as in neuronal and oligodendrocyte 
death, resulting in enhanced recovery after spinal cord injury [204]. Further, scar forming reactive 
astrocytes have been shown to restrict inflammation and decrease lesion volume in a STAT3-
dependent mechanism after spinal cord injury [205, 206]. Additionally, reactive astrocytes have been 
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described to secrete TNF-stimulated gene-6 (TSG-6) within the glial scar, coordinating the formation 
of a hyaluronan-rich matrix and suppressing neuroinflammation [207]. 
In ischemic stroke, astrocytes move towards the lesion resulting in accumulation of reactive 
astrocytes, microgliosis and glial scar formation in animal models of MCAO [208] as well as in the 
human brain after ischemic stroke [209]. This forms a compact border around the lesion, restricting 
the damaged area. Reactive astrocytes display altered expression of molecules involved in cell 
structure, gene transcription, intracellular signaling and energy metabolism, protecting neurons from 
oxidative stress and providing important metabolic support during cerebral ischemia [210]. Both 
reactive astrocytes and microglia secrete stromal cell-derived factor-1 (SDF-1), attracting neuroblasts 
towards the ischemic area [210]. However, as discussed, glial scar formation also interferes with 
neurite regeneration and functional recovery. In response to ischemic stroke, astrogliosis has been 
described to be mediated by repulsive guidance molecule a (RGMa) through TGFβ1 and knockdown 
of RGMa resulted in abolished hypertrophy, cell migration and CSPG secretion [208]. Furthermore 
influencing astrocyte activation by knockdown of apoptosis signal-regulating kinase 1 in mice with 
tMCAO, resulted in reduced glial scar formation, correlating with extended neurites and advanced 
functional recovery [211]. 
In conclusion, the glial scar has been associated with both beneficial and disadvantageous effects, 
but whether these diverse functions offer potential therapeutic targets needs to be further 
investigated. However, current knowledge is suggesting that intervention of specific molecular 
pathways rather than blocking the scarring event itself will have greater therapeutic potential. 
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2 AIMS OF THIS THESIS 
 
In the neurovascular unit tPA mediates activation of latent PDGF-CC for subsequent PDGFRα 
signaling. This has previously been implicated with increased cerebrovascular permeability and 
hemorrhagic complications in ischemic stroke.  
In this thesis we aim to describe the physiological role of tPA and PDGF-CC/PDGFRα signaling in 
the murine brain in development and disease. 
 
Specific aims include: 
Paper I 
To further investigate the biological function of tPA in CNS development and thoroughly 
characterize the tPA -/- mouse with focus on the cerebrovasculature and the ventricular system. 
Paper II 
To explore the role of PDGF-CC/PDGFRα signaling in cerebroventricular development and 
ependymal cell maturation.  
Paper III 
To elucidate the interplay of microglial Mac-1, LRP1 and tPA for tPA mediated PDGF-CC activation 
and subsequent PDGFRα signaling in ischemic stroke. 
Paper IV 
To identify the molecular mechanisms by which imatinib treatment improves stroke outcome by 
influencing BBB integrity and scar formation in ischemic stroke. 
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3 RESULTS AND DISCUSSION 
3.1 Paper I    
tPA Deficiency in Mice Leads to Rearrangement in the 
Cerebrovascular Tree and Cerebroventricular Malformations 
In this paper the role of tPA during CNS development was investigated. Our previous work has 
shown that activation of PDGF-CC and subsequent signaling via its receptor PDGFRα is catalyzed by 
tPA mediated cleavage of latent PDGF-CC [9]. Further studies have implicated this signaling 
pathway to regulate BBB integrity [39]. To better understand the role of tPA and PDGF-CC/PDGFRα 
in cerebrovascular regulation we conducted a detailed analysis of the cerebrovasculature in brains 
from adult tPA deficient (tPA-/-) mice.  
Using immunofluorescent staining analyses, we could demonstrate that life-long deficiency of tPA 
is associated with rearrangements in the cerebrovascular bed towards smaller diameter vessels. 
This rearrangement in the cerebrovascular tree was further characterized by an increased number 
of ERG positive endothelial cells. This was intriguing, since ERG has been associated with vascular 
development [212, 213] and has been shown to control vascular permeability and junctional 
integrity [214]. Accordingly, we found that the increased number of ERG positive cells in tPA 
deficient mice was accompanied by enhanced junctional expression of ZO1. 
To further evaluate the effect of tPA deficiency on the cerebrovasculature we investigated vascular 
mural cell coverage in tPA-/- mice. Mural cells such as pericytes and vascular smooth muscle cells 
are known to play an important role in BBB maintenance and in regulation of blood flow [215, 216] 
and tPA has been described to play a key role in neurovascular coupling [66]. We found a decrease 
in the number of vascular smooth-muscle cell covered, large diameter vessels, resulting in an 
apparent shift in the size towards more ASMA (alpha smooth muscle actin) positive, small 
diameter, vessels. However, the cerebral capillary bed appeared to have normal coverage of 
pericytes. 
Since previous work has shown that tPA mediated activation of PDGF-CC and subsequent PDGFRα 
signaling on perivascular astrocytes regulates cerebrovascular permeability, we investigated 
PDGFRα expression in tPA-/- mice. Interestingly, we found a significant reduction of perivascular 
PDGFRα expression in tPA-/- mice as compared to wild-type controls. Together, the 
cerebrovascular rearrangement described in tPA deficient mice, could partially explain the 
protection of BBB integrity observed in tPA-/- mice [76]. 
In addition to cerebrovascular changes, we noted that tPA deficient mice displayed asymmetric 
lateral ventricles, similar to what had previously been reported for PDGF-CC deficient mice on 
C57BL/6 background [28]. This provided a first in vivo link between tPA and PDGF signaling during 
CNS development. However, PDGF-CC deficient mice had been reported with denudation in their 
ependymal lining, which was not seen in the ependyma of tPA-/- mice, even though the ependyma 
in these mice was abnormal and distorted and did not form a uniform single layer. Further, we also 
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found an increased expression of the tight junction protein ZO1 and GLUT1 in the irregular 
ependymal lining of tPA deficient mice as compared to wild-type controls.  
We conclude from these studies that tPA plays an important role in the development of normal 
cerebral vascularization and normal cerebral ventricular formation. This study enhances our 
understanding of the role of tPA in the CNS and might help to explain how tPA is involved in 
regulation of cerebrovascular integrity and vascular barrier defects in CNS pathology.  
 
3.2 Paper II   
Platelet-derived growth factor-CC Regulates Ependymal Cell 
Maturation in Mice 
We have previously reported malformations of cerebral lateral ventricles and loss of 
neuroependymal integrity in adult PDGF-C deficient mice. These findings were especially 
intriguing, since this had previously not been linked to PDGFRα signaling, and since the molecular 
mechanisms underlying brain ventricle formation and ependymal differentiation still remain 
poorly understood. Loss of neuroependymal integrity has been linked to hydrocephalus and spina 
bifida, a neural tube defect associated with dysfunctional PDGFRα signaling. This strongly 
implicates PDGF-CC/PDGFRα signaling in brain ventricle and ependymal development.  
Here we intended to reveal the molecular mechanism underlying abnormal ventricular 
development in PDGF-C deficient mice. We first examined whether the expansion of the lateral 
ventricles in adult PDGF-C deficient mice might be due to an obstruction of flow in the ventricular 
system. By visualizing the CSF flow in the ventricular cavities using Evans blue dye, we found that 
the dye circulated through the lateral and third ventricle as well as the cerebral aqueduct to the 
fourth ventricle, indicating no obstruction of flow in the ventricular system.  
To determine whether the ventricular abnormalities were present already from birth, or acquired 
during postnatal development, we investigated the prevalence of the cerebral ventricular defects 
in PDGF-C deficient mice during perinatal development. We found a higher proportion of 
asymmetric lateral ventricles in PDGF-C deficient mice compared to wild-type controls as early as 
postnatal day 7. This asymmetry persisted in the deficient mice at later postnatal stages, whereas 
in wild-type mice we did not detect any asymmetric lateral ventricles. 
The cerebral ventricles are lined with a layer of cuboidal, ciliated ependymal cells propelling CSF. 
Previously PDGF-C deficient mice were described with ependymal denudation in the lateral 
ventricles [28]. Thus, we investigated whether these ependymal defects are acquired during 
ependymal cell maturation postnatally. We found delayed maturation of ependymal cells in the 
lateral ventricles of PDGF-C deficient mice, coinciding with an undulation and denudations of the 
ependymal lining. Further, the ependymal defects were accompanied by mild astrogliosis, a repair 
mechanism for ependymal defects and ependymal cell dysfunction [217].  
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During ependymal cell maturation tufts of motile cilia form on the apical surface of ependymal cells 
[131]. Loss or dysfunction of ependymal cilia has been associated with hydrocephalus formation due 
to impaired CSF propulsion, resulting in CSF accumulation and subsequent ventricular expansion 
[119, 124, 127, 128]. However, in Pdgfc-/- mice we found significantly shorter motile cilia, appearing 
disorganized instead of well-organized in tufts as seen in wild-type mice. Since ventricular 
asymmetry in the PDGF-C deficient mice was found to occur prior to ependymal cell maturation and 
motile cilia formation, we speculated that impaired ependymal lining and motile cilia structure might 
only exacerbate ventricular expansion. Given that ependymal cells arise from a subpopulation of 
radial glia cells between E14 and E16 [131], we investigated whether PDGF-CC might influence radial 
glia differentiation resulting in impaired ependymal cell development. By immunofluorescent 
staining, we found Nestin positive cells (a marker for radial glia) mislocalized within the lateral 
ventricular lumen.  
Taken together this suggests that PDGF-CC/PDGFRα signaling in the developing murine brain might 
influence radial glia differentiation and migration, leading to altered ependymal cell maturation and 
motile cilia formation, resulting in asymmetric and enlarged ventricular development. 
 
3.3 Paper III  
Microglial – mediated PDGF-CC Activation Increases 
Cerebrovascular Permeability during Ischemic Stroke 
Previously, we reported that tPA acting on the parenchymal side of the NVU mediates activation of 
latent PDGF-CC and subsequent PDGFRα signaling, resulting in increased BBB permeability and 
intracerebral hemorrhage (ICH) [39]. However, tPA mediated activation of PDGF-CC in vitro has 
been shown to be inefficient, suggesting co-factors to enhance the activation of PDGF-CC in the 
NVU.  
Here we investigated possible co-factors needed for efficient activation of latent PDGF-CC by tPA. 
Earlier studies had shown that one of these co-factors was the endocytic receptor LRP1 [39, 76, 
218]. Using a PAE-α cell line with stable expression of recombinant PDGFRα, our studies 
demonstrated that together with LRP1, the integrin Mac-1 on microglia is necessary to facilitate 
efficient tPA mediated activation of PDGF-CC. In various immunofluorescence analyses we showed 
that in the NVU, Mac-1, LRP1 and PDGFRα are present in close vicinity of each other, promoting 
the hypothesis that Mac-1 and LRP1 act as co-factors for tPA mediated PDGF-CC activation. 
Following ischemic stroke, it has been shown that microglia upregulate expression of Mac-1 and 
that this upregulation coincides with a tPA dependent increase in cerebrovascular permeability. 
Here we showed that intraventricular injections of tPA in Mac-1 deficient mice did not increase 
BBB permeability as compared to wild-type controls, whereas injections of active PDGF-CC did. 
Thus, this suggested that Mac-1 is required for tPA mediated activation of PDGF-CC and that 
activated PDGF-CC acts downstream of Mac-1 and tPA in the control of BBB permeability in vivo. In 
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an experimental model of ischemic stroke (MCAO), Mac-1 deficiency was found to be associated 
with less Evans blue extravasation and preserved BBB integrity compared to wild-type mice. We 
investigated whether this was due to Mac-1 acting as a co-factor for tPA mediated activation of 
PDGF-CC in the NVU, and subsequently injected tPA or active PDGF-CC in the cerebral ventricles 
one hour after MCAO. Active PDGF-CC, but not tPA, was able to increase BBB permeability in Mac-
1 deficient mice, whereas intraventricular injections of tPA and active PDGF-CC both showed 
additional increase in BBB permeability in wild-type mice. Further, following MCAO, Mac-1 
deficient mice showed significantly less PDGFRα phosphorylation around vessels in the ischemic 
penumbra as compared to wild-type mice. This supports that tPA mediated activation of PDGF-CC 
is dependent on Mac-1 and thereby is involved in controlling cerebrovascular permeability via 
PDGFRα.  
In order to see whether Mac-1 on resident microglia or on infiltrating leukocytes is responsible for 
mediating PDGF-CC activation by tPA and subsequent BBB disruption in stroke, CX3CR1-GFP/CCR2-
RFP (R/G) mice were used. These mice express GFP in microglia and macrophages under the 
control of the CXCR1 promotor and RFP in monocytes and macrophages under the control of the 
CCR2 promotor, thus offering a good tool to distinguish microglia, monocytes and monocyte-
derived macrophages and follow the recruitment into the ischemic penumbra. This revealed 
microglia as the prominent cell type present prior to and six hours after MCAO. 24 hours after 
MCAO, monocytes associated with vessels and infiltrating into the brain parenchyma were found, 
although at low numbers. The timing of the various events occurring post MCAO suggests that 
resident microglia is the cellular source of Mac-1 facilitating tPA mediated activation of PDGF-CC in 
the NVU and subsequently leading to loss of BBB integrity during ischemic stroke. To confirm this, 
bone marrow from Mac-1 deficient mice or wild-type mice was transplanted into bone-marrow 
irradiated wild-type or Mac-1 deficient mice respectively. We found that Mac-1 deficient mice 
receiving wild-type bone marrow did not show increased BBB leakage and that Mac-1 deficient 
bone marrow transplanted to wild-type mice did not protect from BBB disruption. This is in line 
with the observation that early activation of PDGF-CC is facilitated by Mac-1 on resident microglia 
rather than on circulating leukocytes.  
Late thrombolysis after ischemic stroke significantly increases the risk of ICH. Accordingly, wild-
type mice have an increased incidence of spontaneous ICH following thrombolysis with tPA five 
hours after MCAO, whereas Mac-1 deficient mice are resistant to the development of ICH, even 
with late tPA treatment for thrombolysis. 
Taken together, we show that Mac-1 together with LRP1 facilitates PDGF-CC activation by tPA in 
the NVU, thus providing a limiting factor for PDGF-CC/ PDGFRα signaling and a way to regulate 
BBB permeability and stroke volume. 
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3.4 Paper IV  
PDGFRα Antagonism Reduces Reactive Gliosis and the Scar 
Formation after Ischemic Stroke in Mice 
Previous studies have demonstrated that the tyrosine kinase inhibitor, imatinib, attenuates BBB 
breakdown, reduces stroke volume and improves the outcome after ischemic stroke via inhibition 
of PDGFRα signaling, both in experimental mouse models [39] and in human patients [150]. 
However, the underlying mechanism of how imatinib ameliorates stroke pathology has not been 
described. 
To investigate molecular changes in the NVU that are induced by ischemic stroke, we performed 
differential gene expression analyses on vascular fragments isolated at different time points after 
induction of ischemia and compared this to vessels isolated from sham-operated murine brains. 
We identified 691 differentially expressed transcripts in the NVU three hours post MCAO and 1417 
differentially expressed transcripts 24 hours post MCAO as compared to sham-operated mice. The 
majority of the upregulated pathways were associated with inflammatory responses, including 
granulocyte adhesion, pro-inflammatory mediators, the acute phase response, integrin signaling as 
well as the complement system. Transcripts associated with immune cell recruitment and cell 
activation were primarily upregulated 24 hours post MCAO, suggesting immune cell recruitment as 
a central response at later time points. This is in line with previous reports, describing immune cell 
recruitment to be more prominent at 48 to 96 hours post MCAO [188]. However, three hours post 
MCAO most of the regulated genes were found to be associated with vascular damage and BBB 
function, including tight- and adherens junction signaling, peptidases and various transporters, 
suggesting a crucial role of pathways related to vascular damage in the early response to MCAO.  
Differential gene expression analyses of vascular fragments isolated from imatinib and PBS treated 
mice after MCAO revealed 122 and 85 differentially expressed transcripts three and 24 hours after 
MCAO, respectively. These were mostly representing mechanisms associated with immune cell 
activation and recruitment, brain metabolism and the injury response and were normalized in 
imatinib treated mice as compared to PBS controls.  
Considering that our gene expression data identified that the immune cell response was affected 
by imatinib treatment, we further examined immune cell infiltration using immunofluorescence 
stainings. We found that imatinib had limited effect on immune cell infiltration but instead 
revealed that imatinib treatment influenced reactive gliosis (acute phase), microglia activation 
(subacute phase) and the scarring response (late subacute to chronic phase) after MCAO. In the 
ischemic border PDGFRα positive NG2-glia appeared condensed and hypertrophic as early as three 
hours post MCAO. However, in imatinib treated mice PDGFRα positive cell condensation appeared 
to be inhibited. Further, imatinib attenuated astrocyte activation and diminished the increased 
expression of GFAP found in PBS treated control animals. This is intriguing, since activation of NG2-
glia and astrocyte activation are hallmarks of the reactive gliosis response to injury. Additionally, 
we found that imatinib influenced scar formation. In PBS treated mice the PDGFRα positive scar 
was unstructured and enlarged as compared to imatinib treated mice, where a significant 
reduction of the scar thickness was evident. This is interesting, since the role of reactive gliosis and 
scar formation in functional recovery and disease outcome is controversial. Often the glial scar has 
 24 
been described as limiting to functional recovery after CNS injury due to inhibition of neurite 
regeneration [194, 196]. However, the glial scar is crucial to restrict the area of damage as well as 
the inflammatory response in order to protect healthy CNS tissue [203]. Thus, a structured scar 
with reduced thickness as seen after imatinib treatment, might be beneficial for recovery and add to 
the improved neurological and functional outcome seen with imatinib treatment after ischemic 
stroke [39, 150].  
Further we described the kinetics of the loss of BBB integrity and showed that imatinib attenuates 
cerebrovascular permeability early after MCAO. Three hours post MCAO, when we detected the 
highest level of BBB permeability, we found a significant decrease in BBB dysfunction in imatinib 
treated mice as compared to PBS controls. At 24 hours post MCAO BBB leakage was less dominant, 
but still approximately 45% decreased in imatinib treated mice as compared to PBS treated mice. 
Further, we found imatinib treatment to preserve PDGFRα and GFAP expression in perivascular 
astrocytes, whereas we found it downregulated in the ischemic center of PBS treated control mice 
three hours after MCAO.  
Collectively we provide valuable insight in the molecular response to ischemic stroke and in the 
mechanism by which imatinib improves stroke outcome. 
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
In the work included in this thesis, we describe the physiological role of tPA (Paper I) and PDGF-CC 
(Paper II) in CNS ventricular and vascular development as well as the mechanism of action of tPA 
mediated PDGF-CC activation in the NVU in an experimental model of ischemic stroke (Papers III and 
IV). The results obtained in these studies offer new insights to tPA mediated PDGF-CC/PDGFRα 
signaling in development and disease.  
In Paper I, we describe an important role of tPA in the development of normal cerebral 
vascularization and ventricular formation. This paper provides a first in vivo link between tPA and 
PDGF-CC in CNS development and enhances our understanding of the role of tPA in the CNS, 
especially in regulation of cerebrovascular integrity. Since our studies revealed that the ventricular 
malformations in tPA deficient mice did not entirely phenocopy the ventricular malformations 
seen in PDGF-C deficient mice, further studies are needed to fully understand these processes. 
In Paper II, we describe a new mechanism involved in ependymal cell development and 
subsequently in malformation and expansion of the cerebral ventricles. This study broadens our 
knowledge of PDGF-CC/PDGFRα signaling in CNS development and potentially offers new 
opportunities to understand radial glia differentiation and migration as well as ependymal cell 
development. In future experiments it will be very interesting to determine the cellular identity of 
the highly proliferative cell type underlying the undulating ependymal cell lining, and whether they 
might stem from the subpopulation of Nestin+ radial glia mislocalized within the ventricular lumen of 
PDGF-C deficient embryos at E14.5 and E16.5. These mislocalized Nestin+ cells do not express 
PDGFRα, suggesting that compromised PDGF-CC/PDGFRα signaling impairs radial glia differentiation, 
and potentially also migration, at an earlier developmental stage. Utilizing PDGF-C 
deficient/PDGFRαGFP/+ double mutant mice will provide further insight into whether and how this 
signaling system regulates these processes. 
In Paper III and Paper IV, we provide novel knowledge on the activation of PDGF-CC in the NVU 
and suggest a mechanism by which blocking PDGF-C/PDGFRα signaling with imatinib improves 
stroke outcome. Our data in Paper III identify Mac-1 as a key player in the activation of PDGF-CC. 
Characterizing these essential interactions in the NVU is critical to understand the regulation of BBB 
integrity in ischemic stroke and might open new doors to potential future therapies. This however 
needs further investigation. Towards this end we report in Paper IV that imatinib treatment 
attenuates BBB permeability and reactive gliosis in the acute phase after ischemic insult and controls 
scar formation at later time points. These data provide valuable insight to further elucidate when 
treatment to restore BBB integrity might be most effective in ischemic stroke patients. Future in 
depth analyses of the differential glial scar formation, including cellular composition and origin, as 
well as effect on tissue regenerative processes such as neurite regrowth and angiogenesis, will help 
to further advance our understanding on the role of this pathway in ischemic stroke. In addition, it 
will be interesting to determine the timing and/or contribution of the various biochemical and 
cellular responses, and subsequently the effect of blocking the respective responses, on disease 
outcome. This, by the use of delayed imatinib treatment following ischemic insult, inflammation-
modulating treatments as well as genetic approaches to target the various compartments of PDGFRα 
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expressing cells. Last, future studies using a monoclonal anti-PDGF-CC antibody to prohibit PDGF-
CC/PDGFRα signaling [219, 220] will reveal if all processes affected by imatinib are indeed driven by 
PDGFRα signaling and might offer a new, more specific way to treat ischemic stroke, but also other 
CNS disorders in which the BBB integrity is compromised and where scarring plays a crucial role.  
 
 
 
 
 
 
 
 
 
“If our brains were simple enough for us to understand them, we’d be so simple that we couldn’t” 
- Ian Stewart 
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